FABIANI, IACOPO
 Distribuzione geografica
Continente #
NA - Nord America 3.603
AS - Asia 2.795
EU - Europa 2.396
SA - Sud America 587
AF - Africa 71
Continente sconosciuto - Info sul continente non disponibili 62
OC - Oceania 7
Totale 9.521
Nazione #
US - Stati Uniti d'America 3.359
SG - Singapore 1.058
IT - Italia 923
CN - Cina 703
RU - Federazione Russa 670
BR - Brasile 464
VN - Vietnam 340
BD - Bangladesh 233
HK - Hong Kong 146
GB - Regno Unito 126
CA - Canada 124
DE - Germania 118
NL - Olanda 118
FR - Francia 103
FI - Finlandia 84
TR - Turchia 61
IN - India 55
SE - Svezia 55
MX - Messico 49
PL - Polonia 44
IE - Irlanda 40
AR - Argentina 36
ID - Indonesia 30
EC - Ecuador 29
ZA - Sudafrica 29
IQ - Iraq 28
ES - Italia 26
PK - Pakistan 21
JP - Giappone 20
UA - Ucraina 19
CO - Colombia 16
AT - Austria 14
MY - Malesia 14
SA - Arabia Saudita 14
IL - Israele 13
LT - Lituania 12
VE - Venezuela 12
JM - Giamaica 11
MA - Marocco 11
TT - Trinidad e Tobago 11
PE - Perù 9
AE - Emirati Arabi Uniti 8
BE - Belgio 8
CR - Costa Rica 8
PY - Paraguay 8
SV - El Salvador 8
UZ - Uzbekistan 8
EG - Egitto 6
GT - Guatemala 6
JO - Giordania 6
AU - Australia 5
BO - Bolivia 5
CH - Svizzera 5
CL - Cile 5
DO - Repubblica Dominicana 5
DZ - Algeria 5
GR - Grecia 5
KE - Kenya 5
KZ - Kazakistan 5
NP - Nepal 5
PR - Porto Rico 5
RO - Romania 5
HN - Honduras 4
LB - Libano 4
CW - ???statistics.table.value.countryCode.CW??? 3
HU - Ungheria 3
MG - Madagascar 3
NI - Nicaragua 3
PH - Filippine 3
SI - Slovenia 3
TH - Thailandia 3
TN - Tunisia 3
TW - Taiwan 3
AL - Albania 2
AO - Angola 2
AZ - Azerbaigian 2
BB - Barbados 2
BG - Bulgaria 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
GD - Grenada 2
HR - Croazia 2
KG - Kirghizistan 2
KR - Corea 2
NO - Norvegia 2
OM - Oman 2
PS - Palestinian Territory 2
UY - Uruguay 2
AG - Antigua e Barbuda 1
BA - Bosnia-Erzegovina 1
CG - Congo 1
CU - Cuba 1
CV - Capo Verde 1
CZ - Repubblica Ceca 1
DM - Dominica 1
EE - Estonia 1
ET - Etiopia 1
GP - Guadalupe 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 9.451
Città #
Dallas 805
Singapore 582
San Jose 391
Ashburn 377
Beijing 234
Council Bluffs 227
Hong Kong 140
Moscow 133
Los Angeles 126
Ho Chi Minh City 120
Milan 109
New York 101
Santa Clara 69
Hanoi 67
Rome 65
São Paulo 59
Phoenix 58
The Dalles 52
Munich 48
Helsinki 47
Lauterbourg 45
Buffalo 44
Hefei 42
Boardman 39
Dublin 39
Naples 39
Florence 38
Warsaw 37
Istanbul 33
London 33
Pisa 32
Montreal 30
Denver 29
Houston 29
Orem 29
Lappeenranta 28
Mexico City 27
Frankfurt am Main 24
Amsterdam 23
Beauharnois 23
Brooklyn 23
Chicago 23
Johannesburg 22
Atlanta 21
Chennai 21
Nuremberg 21
Rio de Janeiro 21
Haiphong 19
Seattle 19
Tokyo 19
Toronto 19
Lucca 17
Da Nang 16
Stockholm 16
Genoa 15
Washington 15
Boston 14
Palermo 14
Poplar 14
Bologna 12
Brescia 12
Cascina 12
Curitiba 12
Manchester 12
Turin 12
Guayaquil 11
Paris 11
Ankara 10
Assago 10
Belo Horizonte 10
Mumbai 10
Quito 10
Brasília 9
Porto Alegre 9
San Francisco 9
Shenzhen 9
Biên Hòa 8
Charlotte 8
Hangzhou 8
Hillsboro 8
Hải Dương 8
Kuala Lumpur 8
Queens 8
Salt Lake City 8
San Salvador 8
Brussels 7
Chengdu 7
Dhaka 7
Figino 7
Goiânia 7
Lahore 7
Milwaukee 7
Shanghai 7
Tel Aviv 7
Vienna 7
Bari 6
Changsha 6
City of London 6
Faisalabad 6
Guangzhou 6
Totale 5.174
Nome #
Left ventricular outflow tract velocity-time integral improves outcome prediction in patients with secondary mitral regurgitation 648
Trastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models 400
Echocardiography-Derived Forward Left Ventricular Output Improves Risk Prediction in Systolic Heart Failure 311
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 287
Atrial amyloidosis: mechanisms and clinical manifestations 279
Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan 275
Disease features and management of cardiomyopathies in women 271
Valve disease in cardiac amyloidosis: an echocardiographic score 269
Assessing cardiac mechanics through left ventricular haemodynamic forces 265
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 262
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 259
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 257
Approccio critico all’interpretazione dei trial cardiovascolari con risultati neutri o negativi 255
Role of Imaging in Cardiomyopathies 254
Valvular heart disease in patients with cardiac amyloidosis 246
Sex-specific associations of myocardial perfusion imaging with outcomes in patients with suspected chronic coronary syndrome 237
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions 236
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 236
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers 231
Use of new and emerging cancer drugs: what the cardiologist needs to know 231
Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook 221
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 216
Cardiovascular toxicity from therapies for light chain amyloidosis 215
The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis 209
Treatment Options in AF Patients with Cancer; Focus on Catheter Ablation 199
Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study 199
Echocardiographic Estimate of Pulmonary Capillary Wedge Pressure Improves Outcome Prediction in Heart Failure Patients with Reduced and Mildly Reduced Ejection Fraction 195
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 194
Advancing Cardiovascular Risk Stratification and Functional Assessment: A Narrative Review of CPET and ESE Applications 192
Magnetic resonance imaging for diagnostic workup of embolic stroke of undetermined source: A systematic review 190
Critical Reading of cardiovascular trials with neutral or negative results 181
Partial Lipodystrophy and LMNA p.R545H Variant 177
Exercise oscillatory ventilation in heart failure and brain–lung–heart–muscle crosstalk 174
Ischemic Heart Disease in Liver Transplant Candidates With High Bleeding Risk: Any Way Out? 172
Galectin-3 and Risk for Cancer or Heart Failure: Does Sex Matter? 171
Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation 168
More cardiopulmonary effort testing needed in HFpEF! 152
Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study 147
Safety and Effectiveness of Sodium-Glucose Co-Transporter 2 Inhibitors in Active Cancer Patients with Heart Failure: Results of the Observational TOSCA Trial 130
Response to ‘Is the left atrium the key in the amyloid imaging lock?’ 126
Serum and Tissue Light-Chains as Disease Biomarkers in AL Amyloidosis 77
Arrhythmic risk prediction in non-dilated left ventricular cardiomyopathy: The role of overlap with arrhythmogenic cardiomyopathy 58
PAWP vs LVEDP During Invasive Cardiopulmonary Exercise Testing: In Search of the Holy Grail of a Hemodynamic Truth in Heart Failure. 49
Totale 9.521
Categoria #
all - tutte 41.051
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.051


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202347 0 0 0 0 4 5 4 6 18 5 5 0
2023/2024246 1 0 48 34 10 22 30 8 6 16 14 57
2024/20252.043 40 48 85 51 121 122 291 414 200 119 256 296
2025/20266.319 359 708 828 915 603 452 549 289 418 422 423 353
2026/2027866 160 162 316 228 0 0 0 0 0 0 0 0
Totale 9.521